Recruitment of Patients in a Phase III Systemic Lupus Erythematosus Study

Case Study

About the Case Study

During the planning of a Phase III Systemic Lupus Erythematosus (SLE) anti-B cell therapy, the Sponsor company called on Allucent to assist in the identification and enrollment of patients.

The purpose of the study was to determine the viability of a biological agent in treating SLE patients whose disease state was severe, aggressively advancing and poorly controlled. SLE is a notoriously difficult-to-diagnose autoimmune disorder with no known cure.

Sites & Locations:
32 across Belarus, Georgia, Guatemala, Mexico, Russia, and Sri Lanka